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The broad ligand-binding characteristic of PPARβ/δ has long hampered identiﬁcation of physiologically-meaningful ligands for
t h er e c e p t o r .T h eo b s e r v a t i o n st h a tt h ea c t i v i t yo fP P A R β/δ is supported by fatty acid binding protein 5 (FABP5), which directly
delivers ligands from the cytosol to the receptor, suggest that bona ﬁde PPARβ/δ ligands both activate the receptor, and trigger the
nuclear translocation of FABP5. Using these criteria, it was recently demonstrated that all-trans-retinoic acid (RA), the activator
of the classical retinoic acid receptor RAR, also serves as a ligand for PPARβ/δ. Partitioning of RA between its two receptors was
found to be regulated by FABP5, which delivers it to PPARβ/δ, and cellular RA binding protein II (CRABP-II), which targets it to
RAR. Consequently, RA activates PPARβ/δ in cells that display a high FABP5/CRABP-II expression ratio. It remains to be clariﬁed
whether compounds other than RA may also serve as endogenous activators for this highly promiscuous protein.
Copyright © 2007 D. C. Berry and N. Noy. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs), the
“lipid sensors,” are activated by fatty acids and various fatty
acid derivatives to regulate the expression of genes involved
in multiple physiological functions. Like other members of
subclass 1 of the superfamily of nuclear hormone receptors,
PPARs interact with the retinoid X receptor (RXR) to form
heterodimers that bind to PPAR response elements (PPRE)
in regulatory regions of speciﬁc target genes [1]. Binding
of cognate ligands to these heterodimers results in recep-
tor activation and in upregulation of target gene transcrip-
tion [2–5]. Three PPAR subtypes, encoded for by three sepa-
rate genes, are known to exist: PPARα,P P A R β/δ,a n dP P A R γ
[6]. PPARα is expressed in liver, heart, muscle, and kidney,
where it regulates fatty acid catabolism. Consequently, ac-
tivation of PPARα lowers serum lipid levels; and synthetic
ligands for this receptor are eﬃcient therapeutic agents in
treatment of hyperlipidemia [7, 8]. PPARγ is expressed pre-
dominantly in adipose tissue and macrophages, where it is
involved in adipocyte diﬀerentiation, regulation of sugar and
lipid homeostasis, and control of inﬂammatory responses
[9, 10]. Thiazolidinediones, synthetic compounds that ac-
tivate PPARγ, are in current use as antidiabetic drugs [11].
Several biological lipids have been suggested to serve as en-
dogenous ligands for PPARs. Thus, it was reported that
PPARα can be activated by 8(S)-HETE and by leukotriene
B4(LTB4)[12,13].Itwasalsosuggestedthatthearachidonic
acidmetabolite15deoxy-delta12,14prostaglandinJ2(PGJ2)
functionsasanendogenousligandforPPARγ [14].However,
the involvement of these and other potential ligands in the
activitiesofPPARsinvivohasnotbeenestablished,andthese
receptors remain classiﬁed as “orphan receptors.”
PPARβ/δ is ubiquitouslyexpressedwithparticularly high
level of expression found in brain, adipose tissue, skeletal
muscle, and skin [15]. This receptor is involved in neuronal
development [16], inﬂammation [17–19], skeletal muscle
lipid oxidation [20], keratinocyte diﬀerentiation, epidermal
barrier recovery, and lipid synthesis for keratinocyte prolif-
eration [21, 22]. PPARβ/δ expression in skin is increased in
hyperproliferative lesions, and in response to inﬂammatory
cytokines during skin injury [18, 19]. Elevation of PPARβ/δ
expression in keratinocytes during skin injury is accompa-
nied by production of an (unknown) endogenous ligand(s),
resulting in protection against apoptotic signals and in en-
hancement of skin repair [18]. These antiapoptotic activities
are mediated, at least in part, by the ability of PPARβ/δ to di-
rectly upregulate the expression of PDK1, thereby activating
the survival factor Akt1 and protecting keratinocytes from
apoptosisinducedbycytokinessuchasTNFα[19,21,23,24].2 PPAR Research
PPARβ/δ is the primary PPAR isotype in skeletal muscle [25]
where it plays a role in ﬁber formation and maintenance [20]
and enhances fatty acid oxidation and mitochondrial respi-
ration [26].
Importantly, it has been reported that PPARβ/δ is in-
volved in regulating lipid and sugar homeostasis and that ac-
tivationofthereceptorresultsinprotectionagainstadiposity
and insulin resistance. These activities appear to stem from
transcriptionalregulationofvariousgenes,includinguncou-
pling proteins 1 and 3, long-chain and very-long-chain acyl
CoA synthetase, and muscle carnitine palmitoyltransferase-
1, resulting in depletion of adipose lipid storage and in de-
creased levels of circulating triglycerides and free fatty acids
[26]. In macrophages, activation of PPARβ/δ induces the ex-
pression of ALDH9, a gene involved in carnitine biosynthe-
sis, and leads to lipid mobilization and increased fatty acid
catabolism [27]. It was also demonstrated that treatment
with a selective PPARβ/δ ligand leads to improvement in
hepatic glucose output, higher glucose disposal, and inhibi-
tion of free fatty acid release from adipocytes [26]. Protective
activities of PPARβ/δ against insulin resistance may also be
mediated by the direct target gene PDK1, which is involved
in mobilization of the insulin-responsive glucose transporter
GLUT4 to the plasma membrane [28].
2. PROPOSED LIGANDS FOR PPARβ/δ
LikeotherPPARs,thenatureofendogenous,physiologically-
meaningful ligands for PPARβ/δ has long remained un-
known. The ligand-binding pocket of this receptor is con-
siderably larger than other nuclear receptors displaying a
t o t a lv o l u m eo f∼1300 ˚ A[ 29–31]. The pocket forms a “Y”
shape comprised of three arms approximately 12 ˚ Ai nl e n g t h
[30, 31]. A solvent-exposed channel allows accessibility into
the ligand binding pocket with an entrance area of approxi-
mately 100 ˚ A with the ability to open even larger due to the
ﬂexibility in surrounding helices [30]. The extensive size of
the pocket is consistent with the promiscuous ligand bind-
ing displayed by the receptor; and raises the possibility that
it may be activated by multiple compounds. Examination
of X-ray crystal structures of bacterially expressed PPARβ/δ
ligand-binding domain revealed that the protein was bound
by fatty acids such as eicosapentaenoic acid (EPA) [30],
11,Z-octadecenoic acid [31], palmitic acid, and stearic acid
[31]. It is worth noting however that, while multiple fatty
acid derivatives can bind to this receptor, not all of these
function as activators. Biological compounds that were re-
ported to activate PPARβ/δ include various leukotrienes and
prostaglandins, such as prostaglandin A1, iloprost, PG15d-
J2, and carbaprostacyclin [32, 33].
3. RETINOIC ACID IS A LIGAND FOR PPARβ/δ
Recent observations suggested that PPARβ/δ is activated by
an unexpected fatty acid, the vitamin A metabolite all-trans-
retinoicacid(RA)(seeFigure 1).ItwasthusreportedthatRA
binds to PPARβ/δ with a Kd of ∼15 nM, displaying an order
of magnitude higher aﬃnity for this subtype as compared to
its aﬃnity towards PPARα and PPARγ [34]. It may be worth
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Figure 1: All-trans-retinoic acid.
noting that the binding aﬃnity for RA towards PPARβ/δ
is over an order of magnitude weaker than the aﬃnity of
RAR towards this ligand, which was reported to be in the
sub-nM range [35]. Nevertheless, RA enhances the ability of
PPARβ/δ, but not other PPAR isotypes, to induce the expres-
sionofareportergenedrivenbyaPPRE[34],suggestingthat
it functions as a selective PPARβ/δ ligand.
RA plays key roles both during embryonic development
and in adult tissue, where it is involved in regulation of cel-
lular metabolism, proliferation, diﬀerentiation, and apopto-
sis. It is well established that many of the pleiotropic activi-
ties of RA are exerted primarily through its ability to regulate
gene expression, and are mediated by the nuclear hormone
receptors termed retinoic acid receptors (RARs) [36, 37].
Like PPARs, RARs heterodimerizes with RXR, the complex
binds to RAR response elements (RAREs) in regulatory re-
gions of target genes, and it enhances transcriptional rates
upon ligand-induced activation. In this fashion, RA also dis-
plays distinct anticarcinogenic activities mediated by RAR-
induced upregulation of genes involved in cell cycle arrest
[38], diﬀerentiation [39, 40], and apoptosis [41–43].
The observations that, in addition to activating RAR, RA
also activates PPARβ/δ, raise the possibility that some of the
biological activities of this hormone may be mediated by an
RAR-independent pathway. An RAR-independent activity of
RA has indeed been suggested by studies of RA functions in
skin maintenance. Hence, while it is well established that RA
isessentialforskinmaintenance[44,45],itwasreportedthat
all RAR subtypes are dispensable for this activity [46]. In ad-
dition, while activation of RAR often results in inhibition of
cell growth [47–49], various reports demonstrated that, in
some cancers, this hormone induces carcinoma cell prolifer-
ation[50],againsuggestingamodeofactionthatismediated
by a pathway other than activation of RAR. Taken together,
the identiﬁcation of RA as a potent ligand for PPARβ/δ,a n d
theobservationsthatthisreceptorcandirectlyupregulatethe
expression of prosurvival and proproliferative genes [24, 51]
raise the intriguing possibility that “nonclassical” proprolif-
erative activities of RA may be mediated by PPARβ/δ.
Indeed, it was demonstrated that, in keratinocytes, RA
functions as a bona ﬁde PPARβ/δ-ligand to induce the ex-
pression of well-known PPARβ/δ-target genes including adi-
pose diﬀerentiation-related protein (ADRP) [52], fasting-
induced adipose factor (FIAF) [53], and PDK1 [24]. As ex-
pression of these genes was found to be induced by RA and
by a selective synthetic PPARβ/δ-ligand, but not by an RAR-
selective ligand [54], the data strongly supported the conclu-
sion that these activities of RA in keratinocytes are mediated
by PPARβ/δ and not by the classical RA receptor RAR. AnD. C. Berry and N. Noy 3
importantquestionraisedbytheseobservationsrelatestothe
mechanism by which partitioning of RA between the two re-
ceptors may be regulated, that is, what underlies the ability
of the hormone to activate RAR in some cells but to target
PPARβ/δ in others?
4. RA IS DELIVERED TO PPARβ/δ BY FATTY
ACID-BINDING PROTEIN 5
In addition to associating with nuclear receptors, many hy-
drophobic compounds bind in cells to members of the fam-
ily of intracellular lipid binding proteins (iLBP). It has been
d e m o n s t r a t e dt h a ts o m ei L B P sc o o p e r a t ew i t hs o m en u c l e a r
receptors in mediating the transcriptional activities of their
common ligands [51, 55–58]. For example, it was shown
that the iLBP termed cellular retinoic acid binding protein
II (CRABP-II) serves to directly deliver RA from the cytosol
to the nucleus where it binds to RAR to form a complex that
mediates direct “channeling” of the hormone from the bind-
ing protein to the receptor. It was demonstrated further that,
by directly delivering RA to RAR, CRABP-II signiﬁcantly en-
hances the transcriptional activity of the receptor, and dra-
matically sensitizes cells to RA-induced, RAR-mediated bio-
logical activities [56, 59].
In addition to CRABP-II, the iLBP family also includes
nine isotypes of fatty acid binding proteins. FABPs are more
promiscuous than CRABPs and they bind a variety of fatty
acids and fatty acid derivatives [51, 60, 61] displaying ligand-
binding selectivities reminiscent of those of PPARs. One
FABP, termed FABP5 (K-FABP, mal1, eFABP), was found to
cooperate with PPARβ/δ in a manner similar to that found
for the cooperation of CRABP-II with RAR. Speciﬁcally, it
wasshownthat,uponbindingofPPARβ/δ-activators,FABP5
mobilizes from the cytosol to the nucleus, and that it delivers
the ligand to its cognate receptor through direct interactions,
thereby signiﬁcantly augmenting the transcriptional activity
of the receptor [51, 54]. Remarkably, while FABP5 binds var-
ious ligands with similar aﬃnities, it mobilizes to the nu-
cleusonlyinresponsetospeciﬁccompounds[51,54].Hence,
PPARβ/δ activators display two distinct functions: they ac-
tivate the receptor, and they trigger the nuclear import of
the PPARβ/δ-associated iLBP, FABP5. The observations that
RA not only induces the transcriptional activity of PPARβ/δ
but also activates the nuclear translocation of FABP5 [54]
raise the level of conﬁdence that this ligand, indeed, func-
tions as a physiologically meaningful activator for the recep-
tor.Itshouldbenotedthat,inthecontextofreportergeneas-
says, RA may activate both RAR and PPARβ/δ in the absence
of their cognate binding proteins if present at high enough
concentrations, but that activation at low concentrations is
signiﬁcantly augmenent by the respective binding proteins
(see, e.g., [56]). These observations suggest that the binding
proteins are necessary for eﬃcient receptor activation under
physiological concentrations of their ligands in vivo.
AvailableinformationthusindicatesthatRAalternatively
activates two diﬀerent nuclear receptors: RAR and PPARβ/δ,
and that the partitioning of this hormone between these re-
ceptors is regulated by two iLBPs that selectively cooperate
with these receptors, CRABP-II, which delivers RA to RAR,
and FABP5, which “channels” RA to PPARβ/δ.H e n c e ,t h e
relative expression levels of the two binding proteins in dif-
ferent cells will determine the spectrum of genes that can be
activated in response to RA, and thus the RA-induced cel-
lular responses. Interestingly, it has been demonstrated that,
in the context of two cell types, keratinocytes and MCF-7
mammary carcinoma cells, and in tumors that arise in vivo
inthemammarycarcinomamousemodelMMTVneu,alter-
nate activation of the two receptors lead to opposing biolog-
ical responses: RA-induced activation of the CRABP-II/RAR
pathway results in inhibition of cell growth, while activation
of FABP5/PPARβ/δ enhances proliferation and enables cell
survival in the face of potent apoptotic agents [54, 59].
5. CONCLUSIONS
The involvement of PPARβ/δ in regulation of keratinocyte
proliferation, skeletal muscle metabolism, inﬂammation,
and lipid homeostasis, together with the recent suggestions
that this receptor may be a target for therapeutic strategies
in treatment of the metabolic syndrome, emphasize the need
foridentiﬁcationofligandsthatactivatethisreceptorinvivo.
The extensive size of its ligand binding pocket and its broad
ligand selectivity raise the possibility that PPARβ/δ may be
activated by multiple compounds, and, perhaps, that diﬀer-
ent ligands serve in this function in diﬀerent cells and/or un-
der diﬀerent physiological circumstances. The observations
that eﬃc i e n ta c t i v a t i o no ft h i sr e c e p t o rr e q u i r e sc o o p e r a t i o n
with FABP5, which speciﬁcally delivers ligands from the cy-
tosol to nuclear PPARβ/δ, provide a new powerful criterion
for identifying physiologically-meaningful ligands. Hence,
such ligands will be required not only to activate the re-
ceptor, but also to trigger the nuclear translocation of the
binding protein. Using these criteria, it was recently demon-
strated that RA is a potent endogenous ligand for PPARβ/δ.
These observations suggest that PPARβ/δ is a retinoid recep-
tor, functioning similarly to RAR and RXR to regulate gene
expression in response to a vitamin A metabolite. The ques-
tion of whether RA is the sole endogenous ligand for this re-
ceptor or whether additional physiologically-meaningful lig-
ands exist remains open and awaits further studies.
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